Definium Therapeutics Doses First Patient in Second Phase 3 Study for Major Depressive Disorder
Summary
Definium Therapeutics announced the dosing of the first patient in Ascend, its second Phase 3 pivotal study for DT120 ODT in Major Depressive Disorder, signaling significant progress in its clinical pipeline.
Key Events
-
Second Phase 3 Study Initiated
Definium Therapeutics has dosed the first patient in Ascend, its second Phase 3 pivotal study evaluating DT120 ODT for the treatment of Major Depressive Disorder (MDD).
-
Advancement of Lead Candidate
The Ascend study builds on positive Phase 2b results and is aligned in design with the ongoing Emerge Phase 3 study for MDD and other trials for generalized anxiety disorder.
-
Future Data Readouts
Topline data from the Ascend study's 12-week double-blind period is anticipated in 2027, following the expected topline readout from the Emerge study in late Q2 2026.
Analysis
Definium Therapeutics has initiated its second pivotal Phase 3 study, Ascend, for DT120 ODT in Major Depressive Disorder (MDD) by dosing the first patient. This marks a significant advancement in the company's lead clinical program, building on positive Phase 2b results and complementing the ongoing Emerge Phase 3 study for MDD. Successful progression through Phase 3 is critical for potential regulatory approval and addresses a substantial unmet medical need in MDD. Investors will now look towards the anticipated topline data from the Emerge study in late Q2 2026, followed by Ascend data in 2027.
At the time of this filing, DFTX was trading at $21.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $6.03 to $26.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.